| Autor: |
Smith MD; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA. misty.smith@pharm.utah.edu.; School of Dentistry, University of Utah, Salt Lake City, 84112, USA. misty.smith@pharm.utah.edu., Woodhead JH; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Handy LJ; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Pruess TH; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Vanegas F; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Grussendorf E; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Grussendorf J; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., White K; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Bulaj KK; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Krumin RK; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Hunt M; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA., Wilcox KS; Epilepsy Therapy Screening Program Contract Site, Department of Pharmacology & Toxicology, University of Utah, Salt Lake City, UT, 84108, USA. |
| Abstrakt: |
The series of experiments herein evaluated prototype drugs representing different mechanisms of antiseizure, antinociceptive or antidepressant action in a battery of preclinical pain models in adult male CF#1 mice (formalin, writhing, and tail flick) and Sprague Dawley rats partial sciatic nerve ligation (PSNL). In the formalin assay, phenytoin (PHT, 6 mg/kg), sodium valproate (VPA, 300 mg/kg), amitriptyline (AMI, 7.5 and 15 mg/kg), gabapentin (GBP, 30 and 70 mg/kg), tiagabine (TGB, 5 and 15 mg/kg), and acetominophen (APAP, 250 and 500 mg/kg) reduced both phases of the formalin response to ≤ 25% of vehicle-treated mice. In the acetic acid induced writhing assay, VPA (300 mg/kg), ethosuximide (ETX, 300 mg/kg), morphine (MOR, 5 & 10 mg/kg), GBP (10, 30, and 60 mg/kg), TGB (15 mg/kg), levetiracetam (LEV, 300 mg/kg), felbamate (FBM, 80 mg/kg) and APAP (250 mg/kg) reduced writhing to ≤ 25% of vehicle-treated mice. In the tail flick test, MOR (1.25-5 mg/kg), AMI (15 mg/kg) and TGB (5 mg/kg) demonstrated significant antinociceptive effects. Finally, carbamazepine (CBZ, 20 and 50 mg/kg), VPA, MOR (2 and 4 mg/kg), AMI (12 mg/kg), TPM (100 mg/kg), lamotrigine (LTG, 40 mg/kg), GBP (60 mg/kg), TGB (15 mg/kg), FBM (35 mg/kg), and APAP (250 mg/kg) were effective in the PSNL model. Thus, TGB was the only prototype compound with significant analgesic effects in each of the four models, while AMI, GBP, APAP, and MOR each improved three of the four pain phenotypes. This study highlights the importance evaluating novel targets in a variety of pain phenotypes. |
Full text from SpringerLink